gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · KNSAHealthcarePharmaceuticals

Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares (KNSA)

$96.12+3.03%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$96.12▲ 149.40% in range
Nov 4, 2025Low $37.92 · High $97.56Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Kiniksa Pharmaceuticals International, plc closed at $96.12 on Nov 4, up 3.03%, 1.5% below its 52-week closing high. Volume of 861.3K shares was 0.93× its 20-day average (close to normal).

Split-adjusted performance: +24.7% over one month, +65.1% over six months, +156.5% over one year.

In the quarter ended Sep 30, 2026, revenue was $285.97M, up 58.1% from a year earlier, with a net margin of 16.6%.

Short interest was 3.8M shares at the Oct 15 settlement (9.6% of float, 6.8 days to cover).

Market cap$7.55B78.6M shares
Revenue · quarter$286.0M+58.1% YoY
Diluted EPS$0.56+143.5% YoY
P/E · TTM68.9×P/S 8.0×
Net margin16.6%Gross 90.3%
Dividend yieldNone
52-week range37.47 – 97.56−1.5% from high
Volume861.3K0.93× 20-day avg
Volatility · 60d54.2%Annualised
Short % of float9.6%6.8 days to cover
Net cash$462.9MCash $568.8M
Next earnings—Not scheduled
Split-adjusted performance
1W +1.0%1M +24.7%3M +25.6%6M +65.1%YTD +133.0%1Y +156.5%3Y +513.0%5Y +792.5%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum96
Revenue growth80
Net margin84
Value (low P/E)17
Size92

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short3.8M−0.4% vs prior
Days to cover6.8Settled Oct 15
% of float9.6%
Short vol. 10d41.5%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
KNSAKiniksa Pharmaceuticals International$96.12+3.03%+65.1%+58.1%16.6%68.9$7.55B
RYTMRhythm Pharmaceuticals$110.68+28.04%+14.6%+46.9%−70.7%—$7.62BCompare
ALKSAlkermes$45.89+0.44%+29.9%+21.8%3.4%—$7.70BCompare
AXSMAxsome Therapeutics$137.00−1.87%−38.5%+51.9%−5.0%—$7.18BCompare
PRAXPraxis Precision Medicines$284.79+1.53%−15.8%———$7.95BCompare
AMRXAmneal Pharmaceuticals$19.95−1.29%+46.5%+9.9%7.2%44.2$6.95BCompare
ORKAOruka Therapeutics$101.41+1.87%+45.3%———$6.71BCompare
IONSIonis Pharmaceuticals$40.15−0.67%−47.8%−40.7%−42.8%—$6.67BCompare
CORTCorcept Therapeutics$79.22−3.31%+51.9%+31.7%16.8%157.2$8.56BCompare

News about Kiniksa Pharmaceuticals International

All news →
Here's Why Kiniksa Pharmaceuticals International, plc (KNSA) is a Strong Momentum StockZacks Investment Research · 17h ago▲ PositiveKiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio ExecutionGlobeNewswire Inc. · Jul 28, 2026▲ PositiveWhy Kiniksa Pharmaceuticals International Stock Raced Nearly 24% Higher TodayThe Motley Fool · Apr 28, 2026▲ Positive

Quick answers

What does Kiniksa Pharmaceuticals International, plc do?
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab.
What is KNSA's market cap?
$7.55B, based on the Nov 4 close of $96.12.
What is KNSA's P/E ratio?
68.9× trailing-twelve-month earnings of $109.57M.
Does Kiniksa Pharmaceuticals International, plc pay a dividend?
No regular cash dividend has been paid in the last year.
How much of KNSA is sold short?
3.8M shares, 9.6% of float, as of Oct 15, 2026.
What sector is KNSA in?
Healthcare, in the Pharmaceuticals industry.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

HQ: London, 366 employeesListed May 24, 2018kiniksa.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology